European Journal of Cancer
VerifiedJournal
The European Journal of Cancer is a peer-reviewed medical journal devoted to cancer research on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), and on cancer epidemiology and prevention. It is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European Cancer Organisation (ECCO), the European Association for Cancer Research (EACR) and the European Society of Breast Cancer Specialists (EUSOMA). The editor-in-chief is Alexander M. M. Eggermont . Source
Actions
Media Outlet details
| Scope | International |
|---|---|
| Language | English |
| Country | France |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Monthly |
| Accepts contributed content | Yes |
Recent Articles
Search ArticlesImmune remodelling and molecular profiling of progressive brain metastases following cranial radiotherapy
KEYWORDS Brain metastasis progression epigenetic signatures genetic profile tumor immune microenvironment immune reprogramming Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. Steindl, A. ∙ Brunner, T.J. ∙ Heimbach, K. ... Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years European Journal of Cancer. 2022; 162:170-181 2.
The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma
Keywords “household income” “localized pancreatic adenocarcinoma” “resection” “chemotherapy” “distance to hospital” 1 Introduction Pancreatic adenocarcinoma is estimated to become the second leading cause of cancer-related mortality by 2030. [1,2] Currently, the best chance of long-term survival for patients with localized disease consists of resection of the pancreatic tumor combined with (neo)adjuvant chemo(radio)therapy.
Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials
Get full text access Log in, subscribe or purchase for full access. References 1. Le Tourneau, C. ∙ Lee, J.J. ∙ Siu, L.L. Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst. 2009; 101:708-720 2. Le Tourneau, C. ∙ Stathis, A. ∙ Vidal, L. ... Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials J Clin Oncol. 2010; 28:1401-1407 3. Postel-Vinay, S. ∙ Collette, L. ∙ Paoletti, X. ...
Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: an integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4)
Keywords colorectal cancer recurrence survival analysis randomized controlled trials prognosis Get full text access Log in, subscribe or purchase for full access. References 1. World Health Organization. Colorectal Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer. (accessed 3 December 2025). 2. Pita-Fernández, S. ∙ Alhayek-Aí, M. ∙ González-Martín, C. ...
International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: the EORTC QLQ-SURV100
Keywords cancer survivorship cancer survivors quality of life patient-reported outcome measures Get full text access Log in, subscribe or purchase for full access. References 1. Organisation for Economic Co-operation and Development (OECD). EU Country Cancer Profiles Synthesis Report 2025. Paris; 2025. 2. Wagle, N.S. ∙ Nogueira, L. ∙ Devasia, T.P. ... Cancer treatment and survivorship statistics, 2025 CA: A Cancer Journal for Clinicians. 2025; 75(4):308-340 3. Chan, R.J. ∙ Nekhlyudov, L.
Fast-Track or Non-Fast-Track Pathways? Association with Prognosis and Mortality in Cancer Patients: A Nationwide Register-Based Cohort Study in Denmark
Key words Neoplasms Fast-track cancer diagnoses Non-fast-track cancer diagnoses Cancer diagnoses difficulty Hard to detect cancers Stage at diagnosis 1 Introduction Cancer remains a leading health challenge, with an estimated 20 million new cases and nearly 10 million deaths worldwide in 2022, with over 35 million new cases predicted by 2050 [1]. Timely diagnosis is critical for improving prognosis.
Patterns of Endpoint Use in Oncology Pragmatic Clinical Trials: A Review of Randomised Studies.
Keywords Pragmatic clinical trials treatment optimisation de-escalation surrogate endpoints Get full text access Log in, subscribe or purchase for full access. References 1. Zabor, E.C. ∙ Kaizer, A.M. ∙ Hobbs, B.P. Randomized Controlled Trials Chest. 2020 Jul 1; 158(1):S79-S87 PubMed PMID: 32658656. 2. Hariton, E. ∙ Locascio, J.J. Randomised controlled trials – the gold standard for effectiveness research BJOG. 2018 Dec 19; 125(13) 3.
VALIDATION OF THE LUNG IMMUNE PROGNOSTIC INDEX IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER: POST HOC ANALYSIS OF THE CASPIAN AND IMPOWER133 PHASE 3 TRIALS
Keywords Lung Immune Prognostic Index LIPI SCLC biomarker immunotherapy Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. Dingemans, A.M.C. ∙ Früh, M. ∙ Ardizzoni, A. ... Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Ann Oncol Off J Eur Soc Med Oncol. 2021 Jul; 32(7):839-853 2. Ganti, A.K.P. ∙ Loo, B.W. ∙ Bassetti, M. ...
The European Organisation for Research and Treatment of Cancer Quality of Life Group: Past Achievements and Future Priorities in Patient-Reported Outcomes in Oncology
Original ResearchArticles in Press116961Open access Affiliations & Notes aDepartment of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands bEuropean Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium cMedical Oncology Department, Hospital Universitario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain dPsycho-Oncology Unit, Institut Curie, Paris, France ePsychology Institute,...
“Methodological considerations in the interpretation of ASCENT-03”
Keywords BREAST CANCER SACITUZUMAB GOVITECAN CHEMOTHERAPY TRIPLE NEGATIVE Get full text access Log in, subscribe or purchase for full access. References 1. Cortés, J. ∙ Punie, K. ∙ Barrios, C. ... Sacituzumab govitecan in untreated, advanced triple-negative breast cancer N Engl J Med. 2025; 393:1912-1925 2. Cortes, J. ∙ Rugo, H.S. ∙ Cescon, D.W. ... KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer N Engl J Med. 2022; 387:217-226 3. Punie, K.